Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicine with over 15 years of experience in oncology drug discovery in both small biotechnology companies and large pharmaceutical companies.
Read MoreDr. Ethan Perlstein is the founder and CEO of Perlara PBC, the first biotech public benefit company established in 2014 that partners with highly motivated and entrepreneurial families and foundations to develop treatments and cures for genetic diseases.
Read MoreMichel Detheux is the co-founder, President, and CEO of iTeos Therapeutics, and has held the role of CEO since the company’s inception in 2012. He previously served as a director at Ludwig Cancer Research from December 2010 to March 2012.
Read MoreArmon Sharei, PhD, is the Chief Executive Officer and Founder of SQZ Biotechnologies, a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies for patients around the world and has active programs in Oncology, Autoimmune and Infectious Diseases, and other serious conditions.
Read MoreThomas is a veteran entrepreneur who has turned creative scientific visions into successful businesses for both startups and established organizations for over 20 years and has co-founded or helped launch several companies, including Intellia Therapeutics and Eleven Biotherapeutics.
Read MoreAndrew Bellinger is chief scientific officer of Verve Therapeutics. He is a general cardiologist at Brigham and Women’s Hospital and is board-certified in cardiovascular medicine and internal medicine. His scientific expertise includes biomedical engineering and drug delivery, computational modeling, pharmacology, clinical strategy and translational medicine.
Read MoreBrian Finrow brings the skills and experience of a lawyer to a position that, in the biotech world, is more typically occupied by a scientist. This is essential to an enterprise like Lumen, which is rethinking drug development from the ground up to emphasize speed, efficiency and ease of delivery, and whose approach is so innovative that traditional ways of thinking about IP and regulatory pathways oftentimes do not apply.
Read MoreJeffrey Goldberg is the president and CEO of Immunitas. Jeff is an experienced biotech program and brand leader with over 20 years of industry experience. He has driven programs from discovery and pre-clinical through IND, clinical trials, NDA, and commercialization in multiple therapeutic areas, including oncology, neurology, renal, and other rare and orphan diseases.
Read MoreTodd Zavodnick has over 20 years of leadership experience in the biopharmaceutical industry. Prior to joining Dermavant in November 2018, Mr. Zavodnick served as Chief Commercial Officer and President of Aesthetics and Therapeutics at Revance.
Read MoreAlison serves as the chief medical officer at Surface Oncology. She has over 20 years of experience in clinical research, oncology drug development and clinical neuro-oncology.
Read MoreNancy Lurker: President & Chief Executive Officer
Our President, CEO, and a director since September 2016, Ms Lurker has broad-ranging experience in the pharmaceutical industry.
Said Saim, PhD: Chief Technology Officer
Dr Saim has more than 25 years of product development experience.
Mike Nally is the Chief Executive Officer of Generate Biomedicines and a CEO-Partner at Flagship Pioneering. Mike brings significant experience leading global organizations and is passionate about working with teams and partners to bring innovations to patients.
Read More
